13F Holdings
中文EN

AIDX 20/20 Biolabs, Inc.

Services-Testing Laboratories · Nasdaq · SEC CIK 1139685 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin29.7%
Operating margin-249.2%
Net margin-317.8%
FCF margin—
EBITDA margin-246.8%

Returns

ROE-1,768.6%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets56.8%
Debt / equity0.00x
Current ratio1.62x
Interest coverage-7.51x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.05M$1.75M
Cost of revenue$1.44M$1.39M
Gross profit$604,541$360,311
R&D expense$592,569$1.26M
SG&A expense$3.34M$4.76M
Operating income-$3.33M-$5.68M
Interest expense$156,207$12,646
Net income-$3.74M-$5.55M
EBITDA-$3.27M-$5.56M
EPS (basic)-0.76-1.16
EPS (diluted)-0.76-1.16
Weighted avg. shares (diluted)4.93M4.80M
Balance sheet
Cash & equivalents$1.03M$1.78M
Receivables$199,954$135,272
Inventory$116,217$47,164
Current assets$1.47M$2.03M
PP&E, net$56,677$116,669
Intangibles$202,264$205,529
Total assets$4.14M$3.58M
Current liabilities$2.46M$1.36M
Total liabilities$4.16M$2.08M
Shareholders' equity-$19,225$1.51M
Shares outstanding5.44M4.82M
Cash flow statement
Operating cash flow-$1.92M-$2.60M
Financing cash flow$1.16M$293,333
Depreciation & amortization$63,257$116,035
Stock-based compensation$516,180$2.18M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.